Here are relevant reports on : lymphedema-diagnostics-therapeutics-market
-
Monoclonal Antibody Therapeutics Market / mABs Therapeutics Market Size by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Global Forecast to 2029
The global monoclonal antibody therapeutics market, valued at US$222.6 billion in 2023, stood at US$252.6 billion in 2024 and is projected to advance at a resilient CAGR of 14.5% from 2024 to 2029, culminating in a forecasted valuation of US$497.5 billion by the end of the period. Driving factors of the market, including clinical trials, encompass increasing prevalence of complex diseases, advancements in biotechnology facilitating targeted treatments, regulatory support expediting approval processes, and robust investments in research and development.
- Published: March 2024
- Price: $ 4950
- TOC Available:
-
Global Nanomedical Devices and Therapeutics Market (2011-2016)
Nanomedicine, an application of nanotechnology in medical science, is an evolving market. It represents an important segment of nanotechnology which will significantly change the course of treating life threatening diseases. This, unlike other treatment options, is significantly expected to enhance efficacy and minimize overall adversities. Toxicity and environmental impact of nanoscale materials are the major problems nanomedicine. Research and development in nanomedicine is expected to offer a pool of novel products which will improve the health of patients. The robust product pipeline for nanobiomaterials poses a health picture of the market creates significant growth opportunities. However these will have to go through stringent testing protocols before commercialization.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 - 2020)
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age. Incidence rate of acute myeloid leukemia is high in men and women over 50 years. The acute myeloid leukemia market is segmented into two types; namely childhood acute myeloid leukemia and adulthood acute myeloid leukemia. The market was dominated by AVD regimen in 2010. However, in 2020, the market is expected to be dominated by AVD regimen, Cyatarabine, and Quizartinib drug.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market – (Pipeline Forecast & Market Forecast in G8 Countries) (2011 – 2020)
The incidence of acute lymphocytic leukemia is high in children from 0 to 14 years than the people aged above 14. It is the most common childhood acute lymphocytic leukemia. However, the acute lymphocytic leukemia may also occur in adults. Acute lymphocytic leukemia distribution depends on age. For instance, 30% of is diagnosed before the age of 5 and 55% of ALL age 15.The acute lymphocytic leukemia market is segmented into two types; namely childhood acute lymphocytic leukemia, and adult acute lymphocytic leukemia. The market was dominated by Hyper-CVAD regimen in 2010. However, in 2020, the market is expected to be equally dominated by Hyper-CVAD and Linker regimen.
- Published: December 2013
- Price: $ 4950
- TOC Available:
-
Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)
Chronic lymphocytic leukemia is the second most common cancer in adult males and rarely occurs in children. The risk of chronic lymphocytic leukemia is closely associated with age. About 90% of chronic lymphocytic leukemia is diagnosed in middle age. Incidence rate of CLL is high in men and women over 50 years of age. The chronic lymphocytic leukemia market is segmented into two types; namely childhood chronic lymphocytic leukemia and adulthood lymphocytic leukemia. The market was dominated by Campath drug in 2010. However, in 2020, the market is expected to be equally dominated by GA101/RG7159 molecule and Arzerra drug.
- Published: December 2011
- Price: $ 4950
- TOC Available:
-
RNAI Technology Market- by Application (Research, Therapeutics) - Global Forecasts to 2019
The report presents the latest advances in RNAi technologies and their clinical implication as a therapeutic platform. It charts the current trends in RNAi therapeutics, and analyzes the opportunities and challenges faced by the RNAi companies. The focus will be on the clinical needs, patented technologies and the competitive landscape across geographies.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Prostate Cancer Therapeutics Market (2010-2020) (Opportunity Analysis, Pipeline Assessment and Global Market Forecast)
Prostate cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer-related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost.
- Published: November 2011
- Price: $ 4950
- TOC Available:
-
Lung Cancer Therapeutics Market (NSCLC & SCLC) - 2010-2020 (Pipeline Assessment and Market Forecast) in G7 countries
Lung cancer is responsible for most of the deaths (due to cancer) across the globe. With just one drug slated to be launched by 2014 – Talactoferrin by Agennix AG, for patients with advanced lung cancer; having failed both chemotherapy and treatments with epidermal growth factor receptor (EFGR) - Tyrosine kinase inhibitor (TKI). Lung cancer is still an area with high unmet need for early diagnosis and limited treatment options in the advanced stages of lung cancer.
- Published: November 2011
- Price: $ 4950
- TOC Available:
-
Veterinary Diagnostics Market by Technology (PCR, ELISA, Lateral Flow Assay, Molecular Diagnostics, Immunodiagnostics), Product (Consumables, Instruments), Animal (Companion, Livestock, Swine), Application (Infectious, Bacteria) - Global Forecast to 2030
The global veterinary diagnostics market, valued at USD 3.42 billion in 2024, stood at USD 3.68 billion in 2025 and is projected to advance at a resilient CAGR of 7.8% from 2025 to 2030, culminating in a forecasted valuation of USD 5.36 billion by the end of the period.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Veterinary PoC Diagnostics Market by Product (Consumables and Instruments), Technology [Immunodiagnostics, Molecular Diagnostics (Isothermal Amplification, PCR, CRISPR)], Animal Type (Companion Animals, Livestock, Poultry) - Global Forecast to 2031
The global veterinary PoC diagnostics market is projected to reach USD 1.72 billion by 2031, growing at a CAGR of 7.7% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: May 2026
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
